TF and neoplasm: A specific anti-TF antibody, called SC1, demonstrates a remarkable efficacy against TF extracellular domain, intracellular PAR2 signaling, and tumor-initiated coagulation, which is efficient against TF-positive triple-negative breast cancer (TNBC) and Pancreatic adenocarcinoma cancer (PaC) cells.